WCLC 2023 Insights: "5-Year Survival of Pembro + Chemo for mNSCLC With PD-L1 Tumor Proportion Score <1%"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

WCLC 2023 Insights: "5-Year Survival of Pembro + Chemo for mNSCLC With PD-L1 Tumor Proportion Score <1%"

By Insights from 2023 WCLC FEATURING Shirish Gadgeel

0 views

October 9, 2023

Comments 0

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

The Use of IO Doublet in PD-L1-Negative NSCLC